US vertebroplasty market to grow double digits.
An analysis of the minimally invasive vertebral compression fracture (VCF) treatment market revealed that the US market is expected continue to expand in the next five years, growing from $365 million in 2006 to more than $650 million by 2011, according to Canadian firm Millennium Research Group (MRG).
The popularity of kyphoplasty and the emergence of new devices and competitors in the vertebroplasty market will fuel this growth, MRG reported.
Vertebroplasty and kyphoplasty are minimally invasive, nonsurgical procedures involving the insertion of a bone needle through soft tissues and the injection of a small amount of bone cement into the vertebral body. The treatments are designed to relieve the pain caused by vertebral compression fractures. Kyphoplasty also uses two proprietary balloon devices that are inserted into the vertebral body and gradually inflated to help restore the vertebrae's prefracture shape and height.
"Currently, Kyphon is the largest player in the minimally invasive VCF treatment market with its kyphoplasty products," noted Kevin Flewwelling, senior analyst at MRG. "However, all the competitors, including Kyphon, Stryker, ArthroCare, Cardinal Health, and Cook, continue to improve the safety, efficacy, and ease of use of their vertebroplasty products. Furthermore, newer competitors like Medtronic Spinal and Biologics, Spine Wave and Spineology are providing practitioners new treatment alternatives to choose from."
For more information on MRG's report, Global Markets for Minimally Invasive Vertebral Compression Fracture Treatments, which includes coverage on industry competitors in this market, visit www.mrg.net.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||NEWS FRONT|
|Publication:||Orthopedic Design & Technology|
|Article Type:||Brief article|
|Date:||Jul 1, 2007|
|Previous Article:||ReAble to acquire IOMED for $22m.|
|Next Article:||Corin's hip resurfacing system approved by FDA.|
|SOs leading package growth.|
|Second quarter surpasses expectations.|